Novartis to begin trial with canakinumab in COVID-19 pneumonia patients

Novartis to begin trial with canakinumab in COVID-19 pneumonia patients

Submitted by admin on April 29, 2020 - 10:21am
Source: 
Pharmaceutical Business Review
News Tags: 
Novartis
COVID-19
pneumonia
clinical trials
canakinumab
Headline: 
Novartis to begin trial with canakinumab in COVID-19 pneumonia patients
snippet: 

Novartis has unveiled plans to begin a phase III clinical study to evaluate canakinumab, an interleukin (IL)-1β blocker, in patients with COVID-19 pneumonia.

Do Not Allow Advertisers to Use My Personal information